Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지
DOI QR코드

DOI QR Code

HPLC Method for the Determination of Nicorandil in Human Plasma

  • Park, Sun-Hee (Department of Pharmacology, College of Medicine, Hanyang University) ;
  • Shin, In-Chul (Department of Pharmacology, College of Medicine, Hanyang University)
  • Published : 2008.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

The present study is to determine of sensitive nicorandil analysis method using HPLC and measure the pharmacokinetics parameters (bioavailability, $C_{max}$, $T_{max}$, Ke, $T_{1/2}$) of nicorandil (5 mg, Tab; Choongwae Pharma Corporation). Plasma (500 ul) was mixed with furosemide (internal standard, 500 ug/ml). Detection wavelength was 256 nm. The mixture of 0.01 M ammonium acetate and acetonitrile 80:20 (v/v) was used mobile phase. The HPLC separation was accomplished on ODC reverse HPLC column. The nicorandil was analyzed by a HPLC system, which consists of CAPCELL PAK C18 column (5 ${\mu}$m, 4.6 × 150 mm) and a chromatography data analysis S/W, using a isocratic mobile phase (mixture of 0.01 M ammonium acetate and acetonitrile 80:20 ) at 1.0 ml/min. Its sensitivity, selectivity, accuracy and precision must be adequate for the bioavailabilty study of nicorandil, and the linearity ($r^2$ ≥ 0.9994) of nicorandil was also proved in the range of 0.05 ug/ml . 3 ug/ml. The pharmacokinetic parameters of nicorandil (5 mg) tablets were measured as the follow. AUC: 0.19 ug/ml·hr, $C_{max}$: 0.14 ug/ml, $t_{max}$: 0.58 hr, Ke: 0.11 hr., $t_{1/2\beta}$: 6.76 hrs. This method is simple and sensitive HPLC method using UV detector for determination of nicorandil in human plasma.

Keywords

References

  1. Andrensek, S., Smidovnik, A., Pecavar, A. and Prosek, M. (1999). Routine and sensitive method for determination of nicorandil in human plasma developed for liquid chromatography with ultraviolet and mass spectrometric detection. J. Chromatogr. 735, 103-109 https://doi.org/10.1016/S0378-4347(99)00411-9
  2. Anonymous (1992). Optimizing antianginal therapy: consensus guidelines. Am. J. Cardiol. 70, 72G-76G https://doi.org/10.1016/0002-9149(92)90030-3
  3. Bachert, E. L. and Fung, H. L. (1993). high-performance liquid chromatographic method for stability and pharmacokinetic studies of nicorandil. J. Chromatogr. 619, 336-341 https://doi.org/10.1016/0378-4347(93)80127-P
  4. Berdeaux, A., Drieu la Rochelle, C., Richard, V. and Giudicelli, J. F. (1992). Differential effects of nitrovasodilators, K channel openers and nicorandil on large and small coronary arteries in conscious dogs. J. Cardiovasc. Pharmacol. 20, S17-S21
  5. Frukawa, K., Itoh, I., Kajiwara, M., Kitamura, K., Suzuki, H., Ito, Y. and Kuriyama, H. (1981). Effects of 2-nicotinamidoethyl nitrate on smooth muscle cells and on adrenergic transmission in guinea-pig and porcine mesenteric arteries. J. Pharmacol. Exp. Ther. 218, 260-268
  6. Hamilton, T. C. and Weston, A. H. (1989). Cromokalin, nicorandil and pinacidil: novel drugs which open potassium channels in smooth muscle. Gen. Pharmacol. 20, 1-9 https://doi.org/10.1016/0306-3623(89)90052-9
  7. Holzmann, S., (1983). cGMP as a possible mediator of coronary arterial relaxation by nicorandil (SG-75). J. Cardiovasc. Pharmacol. 5, 364-370 https://doi.org/10.1097/00005344-198305000-00004
  8. Kukovetz, W., R., Holzmann, S. and Poch, G. (1992). Molecular mechanism of action of nicorandil. J. Cardiovasc. Pharmacol 20, S1-S7
  9. Lablanche, J. M., Bauters, C., McFadden, E. P., Quandalle, P. and Bertrand, M. E. (1993). Potassium channel activators in vasospastic angina. Eur. Heart J. 14, 22-24
  10. Mawatari, K., Nakamura, Y., Shimizu, R., Sate, S., Ijnuma, F. and Watanabe, M. (1996). Fluorimetric determination of nicorandil in human plasma by a high-performance liquid chromatographic- postcolumn ultraviolet detection system equipped with on-line back-pressure tubing. J. Chromatogr. 679, 155-159 https://doi.org/10.1016/0378-4347(96)00031-X
  11. Meisheri, K. D., Cipkus-Dubray, L. A., Hosner, J. M. and Khan, S. (1991). Nicorandil-induced vasorelaxation: Functional evidence for $K^+$ channel-dependent and cyclic GMP-dependent components in a single vascular preparation. J. Cardiovasc. Pharmacol. 17, 903-911 https://doi.org/10.1097/00005344-199106000-00007
  12. Ojha, A. and Pargal, A. (1999). Determination of nicorandil concentrations in human plasma using liquid chromatography. J. Pharm. Biomed. Anal. 21, 175-178 https://doi.org/10.1016/S0731-7085(99)00102-8
  13. Shargel, L., and Yu, A. B. C. (1993). Chapter 10. Bioavailability and bioequivalence. In: Applied Biopharmaceutics and Pharmacokinetics, 3rd Ed., p.193, Appleton & Lange, Norwalk, USA
  14. Why, H. J. and Richardson, P., J. (1993). A potassium channel opener at monotherapy in chronic stable angina pectoris: comparison with placebo. Eur. Heart J. 14, 25-29